The present invention relates to novel biocompatible oxygen gas generating devices that can be implanted into a living subject. In certain embodiments, the oxygen gas generating devices can be used to deliver oxygen gas to tissue in a subject, thereby stimulating tissue growth and repair. In other embodiments, the devices operate by electrolytically splitting endogenous water in a subject. In yet other embodiments, the device further comprises an implantable supercapacitor capable of supplying energy to the oxygen gas generating device.

In some aspects, the present invention provides surgical procedures that comprise applying compositions into and/or onto pelvic tissue to provide support to the pelvic tissue. The injectable hydrogel composition comprises a polysaccharide. In embodiments, the polysaccharide comprises one or more of a glycosaminoglycan, chitosan, hyaluronic acid, dextran, alginic acid and hydroxyethyl starch. In other aspects, the present disclosure pertains to kits that are useful for performing such procedures.

In some aspects, the present invention provides surgical procedures that comprise applying compositions into and/or onto tissue, including supporting tissues (e.g., ligaments, connective tissue, muscles, etc.) for pelvic organs, among other tissues. In other aspects, the present disclosure pertains to compositions that are useful for performing such procedures. In still other aspects, the present disclosure pertains to kits that are useful for performing such procedures.

An adhesion prevention material consisting of: (1) a first agent comprising a gelatin derivative, the gelatin derivative (a) including a structure represented by the following formula, GltnNH—CHR.sup.1R.sup.2, in the formula, Gltn represents a gelatin residue, R.sup.1 represents an alkyl group with 5 to 17 carbon atoms, and R.sup.2 represents a hydrogen atom or an alkyl group with 5 to 17 carbon atoms; (b) having imino group/amino group (molar ratio) of 1/99 to 30/70; and (c) having a weight average molecular weight of 10,000 to 50,000; and (2) a second agent comprising a crosslinker for the gelatin derivative.

A fallopian biocompatible plug can include differently expandable portions. A method of treating a uterine abnormality of a patient includes: providing an endoscope having a working channel; inflating a uterine cavity with a fluid; delivering a biocompatible plug into an ostium of a fallopian tube of the patient, wherein the biocompatible plug is substantially cylindrical in form and configured to be radially expandable, wherein the biocompatible plug is configured to expand in the ostium of the fallopian tube to seal the fallopian tube from the uterine cavity; delivering a resection device through the working channel; and resecting the uterine abnormality.

A biologic material is disclosed. The biologic material comprises a crosslinked structural protein and macrophages seeded on the crosslinked structural protein. A method of use of the biologic material for an immunoregenerative treatment in a patient in need thereof also is disclosed. The method comprises steps of: (1) seeding the macrophages on the crosslinked structural protein, thereby obtaining the biologic material; and (2) implanting the biologic material into the patient.

In some aspects, the present invention provides surgical procedures that comprise applying compositions into and/or onto tissue, including supporting tissues (e.g., ligaments, connective tissue, muscles, etc.) for pelvic organs, among other tissues. In other aspects, the present disclosure pertains to compositions that are useful for performing such procedures. In still other aspects, the present disclosure pertains to kits that are useful for performing such procedures.

Stents and methods for producing stents are provided. The stent includes a polymeric substrate comprised of 10-50% (w/w) of alginate and 45-85% (w/w) of gelatine and further includes a polymeric biodegradable resin for coating said polymeric substrate. The stent can also include a contrast agent. The stent can further include a crosslinking agent. The method for producing the stent includes dissolving the alginate and gelatine in water and stirring to obtain a polymeric substrate. The method also includes adding a crosslinking agent to the substrate, injecting the substrate into a mold to obtain the stent, placing the stent in a first alcohol solution, and placing the stent in a crosslinking agent solution. The method further includes placing the stent in a second alcohol solution, and a series of interchanging drying and immersing steps.

The present disclosure provides a system for injecting a drug eluting construct in a patient. The construct includes multiple cellular based microcaspules, wherein the multiple cellular based microcapsules create at least one of a plurality of layers or sections of microcapsules joined together to comprise an implant. There is a medicinal agent within the microcapsules. A syringe and needle inject the implant constructed of microcapsules into the patient at least one of during and after a surgical procedure. The medicinal agent controllably releases into the patient both immediately and at a delayed time.

A flexible anchor for coupling a suture to a bone is provided. The anchor is composed of non-woven electrospun fibers and has an elongate tubular body that extends from a first end to a second end. The anchor is configured to receive a suture that enters the anchor through a first aperture and exits the anchor through a second aperture. When free ends of the suture are pulled, the anchor transitions from a first configuration to a second anchoring configuration.